SCHEMBL5497110

SCHEMBL5497110

CCOC(OCC)C1CC1

nearest known ligand 0.40

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.40
LMNA P02545 1/20 0.38
SHBG P04278 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methyl Alcohol SCHEMBL27917454 0.95 THRB (0.36) THRBLMNASHBG
SCHEMBL16287489 0.89 SHBG (0.44) THRBLMNASHBG
SCHEMBL16287469 0.87 SHBG (0.48) THRBLMNASHBG
SCHEMBL14743720 0.87 SHBG (0.48) THRBLMNASHBG
SCHEMBL11842539 0.87 SHBG (0.48) THRBLMNASHBG
SCHEMBL28088063 0.87 SHBG (0.48) THRBLMNASHBG
SCHEMBL7301138 0.83 SLC6A2 (0.36) THRBLMNA
SCHEMBL196146 0.81 THRB (0.31) THRB
SCHEMBL2754804 0.77
SCHEMBL8760918 0.76 THRB (0.35) THRBLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0690862-A1 NOVEL QUINOLONE DERIVATIVES AND PROCESSES FOR PREPARING THE SAME KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 1996-01-10 EP claimed
WO-1994015938-A1 NOVEL QUINOLONE DERIVATIVES AND PROCESSES FOR PREPARING THE SAME KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 1994-07-21 WO claimed
US-20130066060-A1 Gene for Identifying Individuals with Familial Dysautonomia THE GENERAL HOSPITAL CORPORATION (US) 2013-03-14 US disclosed
CN-101544581-B Processes for preparation of bicyclic compounds and intermediates therefor DAIICHI SEIYAKU CO 2013-02-06 CN disclosed
CN-101544581-A Processes for preparation of bicyclic compounds and intermediates therefor DAIICHI SEIYAKU CO (JP) 2009-09-30 CN disclosed
US-20090176222-A1 Gene for Identifying Individuals with Familial Dysautonomia THE GENERAL HOSPITAL CORPORATION (US) 2009-07-09 US disclosed
CN-100473645-C Processes for preparation of bicyclic compounds and intermediates therefor DAIICHI SEIYAKU CO (JP) 2009-04-01 CN disclosed
EP-1310487-B1 PROCESSES FOR PREPARATION OF BICYCLIC COMPOUNDS AND INTERMEDIATES THEREFOR DAIICHI SEIYAKU CO (JP) 2007-01-03 EP disclosed
CN-1293054-C Process and intermediates for preparation of bicyclic compounds DAIICHI SEIYAKU CO (JP) 2007-01-03 CN disclosed
US-7074837-B2 Processes for preparation of bicyclic compounds and intermediates therefor DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-07-11 US disclosed
US-20050272797-A1 Processes for preparation of bicyclic compounds and intermediates therefor DAIICHI PHARMACEUTICAL CO., LTD. 2005-12-08 US disclosed
CN-1680294-A Processes for preparation of bicyclic compounds and intermediates therefor DAIICHI SEIYAKU CO (JP) 2005-10-12 CN disclosed
US-20040019223-A1 Processes for preparation of bicyclic compounds and intermediates therefor DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-01-29 US disclosed
CN-1468218-A Process for preparation of bicyclic compounds and intermediates therefor ��һ��������ҩ��ʽ���� 2004-01-14 CN disclosed
EP-1310487-A1 PROCESSES FOR PREPARATION OF BICYCLIC COMPOUNDS AND INTERMEDIATES THEREFOR DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2003-05-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040019223-A1 Processes for preparation of bicyclic compounds and intermediates therefor DCXR, CYP51A1, WEE1 THRB 4320/4885LMNA 1331/4885SHBG 4571/4885
US-20050272797-A1 Processes for preparation of bicyclic compounds and intermediates therefor DCXR, WEE1, CYP51A1 THRB 4304/4885LMNA 1326/4885SHBG 4557/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.